A GGGGCC hexanucleotide repeat expansion in C9orf72, the most frequent genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), acts through both gain of toxicity (repeat RNA and dipeptide-repeat proteins) and reduced C9ORF72 protein. The source study (Zhu et al., 2020) showed in mice that reducing C9ORF72 suppresses repeat-induced autophagy elevation and accelerates dipeptide-repeat accumulation, gliosis, neuronal loss and early death, leaving open the molecular function of C9ORF72 in neurons, the causal necessity and sufficiency of autophagy impairment, the environmental basis of knockout-mouse phenotypic variability, and how to reduce repeat-derived toxicity without further lowering C9ORF72. Subsequent work finds these strands sharpened (identified GEF/GAP substrates, microbiome modifiers, failed first-generation ASO trials) but unresolved, so the problem remains open.

Background

Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease of motor neurons, and frontotemporal dementia (FTD) is a related degeneration of frontal and temporal cortex; the two syndromes share genetic causes, most commonly an expanded GGGGCC (G4C2) hexanucleotide repeat in the first intron of the C9orf72 gene. The expansion causes disease through a combination of gain of toxicity — repetitive RNA foci that sequester RNA-binding proteins, plus five dipeptide-repeat (DPR) proteins produced by repeat-associated non-AUG (RAN) translation, a noncanonical translation mechanism that initiates without a start codon — and haploinsufficiency, because transcription through the expanded repeat is impaired, lowering C9ORF72 protein levels in patients. C9ORF72 is a DENN-domain protein that forms a trimeric complex with SMCR8 and WDR41; DENN-domain proteins act as guanine-nucleotide exchange factors (GEFs), which activate small GTPases of the RAB and ARF families by loading them with GTP, thereby controlling membrane trafficking, and structural work later showed the C9ORF72 complex can also act as a GTPase-activating protein (GAP), which does the opposite, accelerating GTP hydrolysis and thereby switching the GTPase off. Autophagy (macroautophagy) is the principal lysosomal degradation pathway for aggregated proteins and organelles: initiation by the ULK1 kinase complex (the autophagosome-initiating kinase cluster that starts the pathway), autophagosome formation marked by lipidated LC3 (LC3-II, a membrane-bound form of the LC3 protein that decorates growing autophagosomal membranes), and fusion of autophagosomes with lysosomes, which in mammalian cells requires the HOPS complex (homotypic fusion and vacuole protein sorting, a multi-subunit tethering factor recruited by RAB GTPases). Because DPR proteins are cleared largely by autophagy, the pathways intersect: reduced C9ORF72 could plausibly slow DPR clearance and so synergize with repeat gain of toxicity. The source study (Zhu et al., Nature Neuroscience 2020) tested this in mice: inactivating one or both endogenous C9orf72 alleles in mice expressing repeat transgenes (66 repeats delivered somatically by AAV9, an adeno-associated virus serotype 9 gene-delivery vector, or a 450-repeat bacterial artificial chromosome (BAC) transgene, an engineered genomic fragment carrying the repeat) provoked or accelerated early death, exacerbated cognitive deficits, hippocampal neuron loss, glial activation and DPR accumulation, while reducing C9ORF72 alone did not change baseline levels of LC3 or p62 (an autophagy cargo receptor that accumulates when autophagy fails); crucially, reduced or absent C9ORF72 suppressed the repeat-mediated elevation of LC3-I/II, i.e. reduced C9ORF72 blunted the autophagy induction that repeats normally provoke. The paper's discussion left four issues open: (1) C9ORF72 was only 'a GEF for as yet unidentified small G protein(s)', with conflicting reports on whether it acts at autophagy initiation (Rab1a/ULK1), on flux via RAB8a/RAB39b, on mTOR (mechanistic target of rapamycin, a kinase whose activity normally suppresses autophagy) signaling, or on stress-granule clearance (stress granules are ribonucleoprotein aggregates of stalled translation machinery); (2) the evidence linked reduced C9ORF72, suppressed autophagy induction and greater DPR burden only correlatively — the consequence of reduced autophagy 'may be' increased DPR accumulation, a hedge, with no in-vivo test of necessity or sufficiency; (3) independent C9orf72 knockout lines generated from the same KOMP (Knockout Mouse Project) ES cells on the same C57BL/6J background showed sharply discordant premature-death and immune phenotypes across laboratories, suggesting unidentified housing, food or microbiome factors; (4) the therapeutic rationale — antisense oligonucleotides (ASOs), synthetic DNA/RNA analogs that recruit the cellular enzyme RNase H to degrade a target RNA, directed at sequences adjacent to the repeat so as to lower repeat-containing RNA without lowering the C9ORF72-encoding mRNAs — was entering phase 1 trials with no evidence about how to combine gain-of-toxicity reduction with preservation of C9ORF72 function. Post-2020 work gives the modern frame for each strand: structural and biochemical studies identified the C9ORF72 complex as a GAP for ARF1, RAB8A and RAB11A and as a GEF for RAB39A (enabling HOPS-mediated autophagosome–lysosome fusion), with its RAB8A GAP activity required for lysosomal membrane repair in microglia; the gut microbiome was shown to modify inflammation and premature death in C9orf72-mutant mice; and first-generation ASO trials in C9orf72 ALS (BIIB078, WVE-004) failed to show clinical benefit. What still stands between these advances and closure is the subject of the problem statement.

Problem Statement

The common objective is to determine, mechanistically and translationally, how much of C9ORF72-repeat-expansion ALS/FTD is due to loss of C9ORF72 function, and to convert that knowledge into a therapy — building on the source study's demonstration (Zhu et al. 2020) that reduced C9ORF72 suppresses repeat-induced autophagy elevation while accelerating DPR accumulation, gliosis, neuronal loss and early death in mice. Four jointly supporting questions, as posed by the source and its 2020-2026 follow-ups: (1) Molecular function — identify the physiologically relevant small-GTPase substrate(s) of the C9ORF72-SMCR8(-WDR41) complex in neurons (candidates now include ARF1, RAB8A and RAB11A as GAP substrates, and RAB39A, together with the earlier-reported related RAB39B, as GEF substrates) and the discrete autophagy step(s) it regulates in vivo (initiation, autophagosome formation or maturation, autophagosome-lysosome fusion, lysosomal repair, or selective autophagy of stress granules), and determine whether C9ORF72 loss affects neuronal autophagic flux cell-autonomously or indirectly through non-neuronal cells such as microglia. (2) Causal hierarchy — establish experimentally, in vivo, whether autophagy impairment is necessary and sufficient for the accelerated DPR accumulation and subsequent neuronal loss provoked by reduced C9ORF72, by directly manipulating the implicated autophagy step in repeat-expressing animals with genetically reduced C9ORF72. (3) Environmental modifiers — resolve how microbiome and other environmental factors interact with C9ORF72 deficiency to modulate disease (the immune and premature-death component of knockout-line variability is now explained by gut microbiome composition, but its interaction with neurological vulnerability in repeat-expressing models is not). (4) Therapy — determine how to reduce repeat-containing RNA and DPR production while preserving or restoring beneficial C9ORF72 function, given that first-generation repeat-targeting ASOs (BIIB078; the variant-selective WVE-004 approach) engaged CSF (cerebrospinal fluid) biomarkers but failed to alter clinical progression or CNS pathology, and that restoring C9ORF72 expression or enhancing autophagic clearance as a treatment for DPR-driven pathology remains untested in the clinic. The four questions are jointly posed: (1) and (2) define the mechanism the therapy in (4) must preserve or substitute, and (3) bounds the environmental contribution any therapeutic claim must control for.

References

  1. Zhu Q, Jiang J, Gendron TF, McAlonis-Downes M, Jiang L, Taylor A, Diaz Garcia S, Ghosh Dastidar S, Rodriguez MJ, King P, Zhang Y, La Spada AR, Xu H, Petrucelli L, Ravits J, Da Cruz S, Lagier-Tourenne C, Cleveland DW. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nature Neuroscience 23(5):615-624 (2020). doi:10.1038/s41593-020-0619-5, https://doi.org/10.1038/s41593-020-0619-5
  2. Burberry A, Wells MF, Limone F, Couto A, Smith KS, Keaney J, Gillet G, van Gastel N, Wang JY, Pietilainen O, Qian M, Eggan P, Cantrell C, Mok J, Kadiu I, Scadden DT, Eggan K. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature 582(7810):89-94 (2020). doi:10.1038/s41586-020-2288-7, https://doi.org/10.1038/s41586-020-2288-7
  3. Polymenidou M. A Gut Feeling about C9ORF72. Trends in Immunology 41(9):755-757 (2020). doi:10.1016/j.it.2020.07.012, https://doi.org/10.1016/j.it.2020.07.012
  4. Tang D, Sheng J, Xu L, Zhan X, Liu J, Jiang H, Shu X, Liu X, Zhang T, Jiang L, Zhou C, Li W, Cheng W, Li Z, Wang K, Lu K, Yan C, Qi S. Cryo-EM structure of C9ORF72-SMCR8-WDR41 reveals the role as a GAP for Rab8a and Rab11a. Proceedings of the National Academy of Sciences 117(18):9876-9883 (2020). doi:10.1073/pnas.2002110117, https://doi.org/10.1073/pnas.2002110117
  5. Su MY, Fromm SA, Remis J, Toso DB, Hurley JH. Structural basis for the ARF GAP activity and specificity of the C9orf72 complex. Nature Communications 12:3786 (2021). doi:10.1038/s41467-021-24081-0, https://doi.org/10.1038/s41467-021-24081-0
  6. Nörpel J, Cavadini S, Schenk AD, Graff-Meyer A, Hess D, Seebacher J, Chao JA, Bhaskar V. Structure of the human C9orf72-SMCR8 complex reveals a multivalent protein interaction architecture. PLOS Biology 19(7):e3001344 (2021). doi:10.1371/journal.pbio.3001344, https://doi.org/10.1371/journal.pbio.3001344
  7. Zhang S, Tong M, Zheng D, Huang H, Li L, Ungermann C, Pan Y, Luo H, Lei M, Tang Z, Fu W, Chen S, Liu X, Zhong Q. C9orf72-catalyzed GTP loading of Rab39A enables HOPS-mediated membrane tethering and fusion in mammalian autophagy. Nature Communications 14:6360 (2023). doi:10.1038/s41467-023-42003-0, https://doi.org/10.1038/s41467-023-42003-0
  8. Li S, Xu S, Li F, Zhao Q, Zhang P, Guan Q, Sun X, Bi J, Xiao H, Tang Y, Peng C, Chen Q, Wang Y, Yang M. The C9orf72/SMCR8 complex maintains microglial homeostasis via RAB8A-ESCRT-mediated lysosomal repair. The EMBO Journal 45(13):4531-4568 (2026). doi:10.1038/s44318-026-00817-w, https://doi.org/10.1038/s44318-026-00817-w
  9. Jiang L, Zhang T, Lu K, Qi S. The progress in C9orf72 research: ALS/FTD pathogenesis, functions and structure. Small GTPases 13(1):56-76 (2022). doi:10.1080/21541248.2021.1892443, https://doi.org/10.1080/21541248.2021.1892443
  10. Beckers J, Tharkeshwar AK, Van Damme P. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy 17(11):3306-3322 (2021). doi:10.1080/15548627.2021.1872189, https://doi.org/10.1080/15548627.2021.1872189
  11. Diab R, Pilotto F, Saxena S. Autophagy and neurodegeneration: Unraveling the role of C9ORF72 in the regulation of autophagy and its relationship to ALS-FTD pathology. Frontiers in Cellular Neuroscience 17:1086895 (2023). doi:10.3389/fncel.2023.1086895, https://doi.org/10.3389/fncel.2023.1086895
  12. Banerjee P, Mehta AR, Nirujogi RS, Cooper J, James OG, Nanda J, Longden J, Burr K, McDade K, Salzinger A, Paza E, Newton J, Story D, Pal S, Smith C, Alessi DR, Selvaraj BT, Priller J, Chandran S. Cell-autonomous immune dysfunction driven by disrupted autophagy in C9orf72-ALS iPSC-derived microglia contributes to neurodegeneration. Science Advances 9(16):eabq0651 (2023). doi:10.1126/sciadv.abq0651, https://doi.org/10.1126/sciadv.abq0651
  13. Ma L, Liang C, Wang J, Chang Q, Wang Y, Zhang W, Du Y, Sadan J, Chen JF. Reversing lysosome-ribosome circuit dysregulation mitigates C9FTD/ALS neurodegeneration and behaviors. Human Molecular Genetics 32(8):1252-1265 (2023). doi:10.1093/hmg/ddac271, https://doi.org/10.1093/hmg/ddac271
  14. de Calbiac H, Renault S, Haouy G, Jung V, Roger K, Zhou Q, Campanari ML, Chentout L, Demy DL, Marian A, Goudin N, Edbauer D, Guerrera C, Ciura S, Kabashi E. Poly-GP accumulation due to C9orf72 loss of function induces motor neuron apoptosis through autophagy and mitophagy defects. Autophagy 20(10):2164-2185 (2024). doi:10.1080/15548627.2024.2358736, https://doi.org/10.1080/15548627.2024.2358736
  15. Lin LT, Shenouda M, McGoldrick P, Lau A, Robertson J. C9orf72 deficiency impairs the autophagic response to aggregated TDP-25 and exacerbates TDP-25-mediated neurodegeneration in vivo. Acta Neuropathologica Communications 13:136 (2025). doi:10.1186/s40478-025-02061-5, https://doi.org/10.1186/s40478-025-02061-5
  16. Tsitkov S, Raju A, Wu J, Li J, Lim RG, Wu Z, Bistami NA, Answer ALS Consortium, Van Eyk JE, Svendsen CN, Rothstein JD, Glass JD, Finkbeiner S, Kaye JA, Thompson LM, Fraenkel E. Wild-type C9orf72 expression is a genetic modifier of C9-ALS survival. medRxiv preprint (2026). doi:10.64898/2026.02.06.26345684, https://doi.org/10.64898/2026.02.06.26345684
  17. Tran H, Moazami MP, Yang H, McKenna-Yasek D, Douthwright CL, Pinto C, Metterville J, Shin M, Sanil N, Dooley C, Puri A, Weiss A, Wightman N, Gray-Edwards H, Marosfoi M, King RM, Kenderdine T, Fabris D, Bowser R, Watts JK, Brown RH Jr. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nature Medicine 28(1):117-124 (2022). doi:10.1038/s41591-021-01557-6, https://doi.org/10.1038/s41591-021-01557-6
  18. van den Berg LH, Rothstein JD, Shaw PJ, Babu S, Benatar M, Bucelli RC, Genge A, Glass JD, Hardiman O, Libri V, Mobach T, Oskarsson B, Pattee GL, Ravits J, Shaw CE, Weber M, Zinman L, Jafar-Nejad P, Rigo F, Lin L, Ferguson TA, Gotter AL, Graham D, Monine M, Inra J, Sinks S, Eraly S, Garafalo S, Fradette S. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. The Lancet Neurology 23(9):901-912 (2024). doi:10.1016/S1474-4422(24)00216-3, https://doi.org/10.1016/S1474-4422(24)00216-3
  19. McEachin ZT, Chung M, Stratton SA, Han C, Kim WJ, Sheth U, Thomas EV, Issenberg E, Kamra T, Merino P, Levites Y, Raj N, Dammer EB, Duong DM, Ping L, Shantaraman A, Trautwig AN, Gadhavi J, Assefa E, Gearing M, Kelly KM, Roemer SF, DeTure M, Asress S, Kukar T, Fournier C, Dickson DW, Petrucelli L, Golde TE, Oskarsson B, Gendron TF, Seyfried NT, Glass JD. Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS. Cell 188(23):6424-6435.e17 (2025). doi:10.1016/j.cell.2025.07.045, https://doi.org/10.1016/j.cell.2025.07.045
  20. Liu Y, Andreucci A, Iwamoto N, Yin Y, Yang H, Liu F, Bulychev A, Hu XS, Lin X, Lamore S, Patil S, Mohapatra S, Purcell-Estabrook E, Taborn K, Dale E, Vargeese C. Preclinical evaluation of WVE-004, an investigational stereopure oligonucleotide for the treatment of C9orf72-associated ALS or FTD. Molecular Therapy - Nucleic Acids 28:558-570 (2022). doi:10.1016/j.omtn.2022.04.007, https://doi.org/10.1016/j.omtn.2022.04.007
  21. Mizielinska S, Hautbergue GM, Gendron TF, van Blitterswijk M, Hardiman O, Ravits J, Isaacs AM, Rademakers R. Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics. The Lancet Neurology 24(3):261-274 (2025). doi:10.1016/S1474-4422(25)00026-2, https://doi.org/10.1016/S1474-4422(25)00026-2
  22. Erdi-Krausz G, Shaw PJ. Antisense oligonucleotide therapy in amyotrophic lateral sclerosis. Current Opinion in Neurology 38(5):574-580 (2025). doi:10.1097/WCO.0000000000001413, https://doi.org/10.1097/WCO.0000000000001413
  23. Meijboom KE, Abdallah A, Fordham NP, Nagase H, Rodriguez T, Kraus C, Gendron TF, Krishnan G, Esanov R, Andrade NS, Rybin MJ, Ramic M, Stephens ZD, Edraki A, Blackwood MT, Kahriman A, Henninger N, Kocher JPA, Benatar M, Brodsky MH, Petrucelli L, Gao FB, Sontheimer EJ, Brown RH Jr, Zeier Z, Mueller C. CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nature Communications 13:6286 (2022). doi:10.1038/s41467-022-33332-7, https://doi.org/10.1038/s41467-022-33332-7
  24. Gilbert JW, Kennedy Z, Godinho BMDC, Summers A, Weiss A, Echeverria D, Bramato B, McHugh N, Cooper D, Yamada K, Hassler M, Tran H, Gao FB, Brown RH Jr, Khvorova A. Identification of selective and non-selective C9ORF72 targeting in vivo active siRNAs. Molecular Therapy - Nucleic Acids 35(3):102291 (2024). doi:10.1016/j.omtn.2024.102291, https://doi.org/10.1016/j.omtn.2024.102291
  25. Sattler R, Traynor BJ, Robertson J, Van Den Bosch L, Barmada SJ, Svendsen CN, Disney MD, Gendron TF, Wong PC, Turner MR, Boxer A, Babu S, Benatar M, Kurnellas M, Rohrer JD, Donnelly CJ, Bustos LM, Van Keuren-Jensen K, Dacks PA, Sabbagh MN; Attendees of the inaugural C9ORF72 FTD/ALS Summit. Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit. Neurology and Therapy 12(6):1821-1843 (2023). doi:10.1007/s40120-023-00548-8, https://doi.org/10.1007/s40120-023-00548-8